2011 Reaxys PhD Prize opens for entries
Global competition for PhD students of chemistry
The prize will be awarded for original and innovative research in organic, organometallic and inorganic chemistry to the candidates that demonstrate excellence in methodology and approach.
Three prizewinners will each receive US$2,000 and will be invited to present their research at the Winners’ Symposium during the 14th Asian Chemical Congress, which takes place from 5–8 September in Bangkok, Thailand.
David Evans, scientific affairs director at Elsevier Properties, said: ‘The Reaxys PhD Prize celebrates innovation and creativity in chemistry research from around the world, values which lie at the heart Reaxys itself.’
He continued: ‘In 2010 we received more than 300 submissions from around the world covering the breadth of modern chemistry. The quality of research was outstanding, and the finalists and winners are clearly at the cutting edge of chemistry research. A high bar has been set for 2011.’
All entries will be evaluated by a review board of leading international chemists, chaired by the Professor A G M Barrett, Imperial College London, UK; Professor B M Trost, Stanford University, US; and Professor H N C Wong, Chinese University of Hong Kong, China, who are members of the Reaxys Advisory Board.
All submissions must include a PhD Supervisor letter of recommendation, a CV and a representative peer-reviewed piece of published research. Entries should be submitted by 28 February to the Reaxys PhD Prize website.
Elsevier Properties SA a division of scientific publisher Reed Elsevier that manages intellectual property. It owns the PharmaPendium, Beilstein and Reaxys databases.
You may also like
Research & Development
COVID-19 immunity lowers the risk of a new pandemic
Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Cytiva enters research partnership with SRTIGET for next-gen genomic medicine
The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development
Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus
Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
Research & Development
ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology
Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents